Benlysta is a man-made antibody that reduces the activity of immune cells (B-cells) in patients with systemic lupus erythematosus (SLE or lupus). Antibodies produced by defective B-cells contribute to development of SLE.

What does Benlysta treat

Benlysta is used for the treatment of adults with active, antibody-positive SLE and receiving other SLE therapies.

How effective is Benlysta

58% of Benlysta treated individuals compared to 44% in the placebo group improved after 52 weeks of treatment.

Most of the improvement were in symptoms related to muscle, skeletal system, skin, mucous membranes, and immune system.

What are interesting facts about Benlysta

Targets B-cells

Administered monthly after the initial doses

Provides additional benefit when combined with standard SLE treatment

Benlysta dosing

10 mg/kg intravenous infusion at 2-week intervals for 3 doses, then every 4-weeks. Each infusion lasts one hour.

What is the cost of Benlysta

Each vial cost about $1477.26 and the yearly cost is about $35,000 without insurance.